March 26 (Reuters) - Verona Pharma Plc:
* VERONA PHARMA REPORTS POSITIVE TOP-LINE DATA FROM PHASE 2B CLINICAL TRIAL OF RPL554 FOR MAINTENANCE TREATMENT OF COPD
* PRIMARY ENDPOINT MET; RPL554 PRODUCED CLINICALLY AND STATISTICALLY SIGNIFICANT IMPROVEMENTS IN LUNG FUNCTION AT ALL DOSES
* VERONA PHARMA - CLINICALLY RELEVANT SECONDARY ENDPOINTS WERE ALSO MET, INCLUDING STATISTICALLY SIGNIFICANT, PROGRESSIVE IMPROVEMENTS IN COPD SYMPTOMS
* RPL554 WAS WELL TOLERATED AT ALL DOSE LEVELS IN THIS FOUR WEEK 400 PATIENT STUDY Source text for Eikon: Further company coverage:
